Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial
2024; American Thoracic Society; Volume: 210; Issue: 11 Linguagem: Inglês
10.1164/rccm.202401-0165oc
ISSN1535-4970
AutoresAva Y Xu, Gustavo E. Velásquez, Nan Zhang, Vincent Chang, Patrick Phillips, Payam Nahid, Susan E. Dorman, Ekaterina V. Kurbatova, William C. Whitworth, Erin Sizemore, Kia Bryant, Wendy Carr, Nicole Brown, Melissa Engle, Nhung Viet Nguyen, Pheona Nsubuga, Andreas H. Diacon, Kelly E. Dooley, Richard E. Chaisson, Susan Swindells, Radojka M. Savić,
Tópico(s)Tuberculosis Research and Epidemiology
ResumoOptimizing pyrazinamide dosing is critical to improve treatment efficacy while minimizing toxicity during tuberculosis treatment. Study 31/AIDS Clinical Trials Group A5349 represents the largest phase 3 randomized controlled therapeutic trial to date for such an investigation.
Referência(s)